Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They will still be on guard with the 390 area and early Nov
And tomorrow and every day after
Good vid. I'm hopeful. I've had my fill of the bearishness and since you and I have been loading longs recently we may be very happy campers.
I might add, the lack of bullish movement with the garbage U products, falls in line with his potential theories.
Can you imagine where the price will go on uvix, uvxy etc if this is a double bottom? My 50 cent bid might not be out of line
Thanks for sharing mannken
Max pain market
https://www.zerohedge.com/the-market-ear/maxpainmarket
that's what I have targeted 3900-3950 on suggested wave patterns
and when I will move back to cash in 401k 'if the pattern plays
still holding Jnug core, sold 100sh today, 680 remaining for a incremental scale out into 1st /2nd week of Oct, no rush, once bullion starts moving, it can go vertical like the greenback did
Vix 23-25 range also possible
Very possible, for starters
very close to filling 15.26 gap yesterday
on a good note, 20ma golden cross above 50ma
give it some time for back filling and converging with mid bollie 20ma, unless there is another event that jolts markets beforehand
I will be looking at labd next week and probably should have grabbed Boil this morning without waiting for NG trend line reconnect at 6.30 since we know markets never give the easy trade lol
Vix annihilation
Uvix bidding 50 cents
Market looks like it wants to blow through 370
Sold half labu 7.44, May re-nter a dip.
Still holding my $6 FNGU
Still holding jnug finally green today in my portfolio
Vix may fall back to 25-27 range imo
what happens if Friday's PCE inflation report comes in soft
I'm assuming traders (short side) are not positioned for that, geez all hell will break loose to the upside
nonetheless,
I thought of a good algo to write
% of analyst and pundits making new market high predictions Q4 2021 before market top = 100%
% of analyst and pundits making new market low predictions now = 100%
market never giveth what its expected to giveth, nature law maybe? ;)
exciting times
still watching BOIL in next day or so for possible entries, would like to see NG 6.30 on trend line
last night started with a futs dump on AAPL news with sentiment extreme fear and SP Put land more crowded than ...'punchline'
followed by BOE QE pivot this morning
why its super dangerous piling on shorts when sentiment, put/call ratio and dollar RSI 80 is lined up like that
its going to take more than several days for the Put crowd to unwind and rebalance the ratio
/imo
Currently my sell on uvix looks good now
Labu fngu jnug nice moves
oh boy, hedge funds threw out miners last few weeks like landfill relics lol
Rule #11
BOE pivots? don't know all the details but continue playing until the bank has enough paper money to operate again lol
https://www.zerohedge.com/markets/bank-england-capitulates-restarts-qe-due-significant-dysfunction-bond-market-material-risk
Cashed out on $LABU $6.84 my reason is BIIB made its huge move this morning up $100 per share and it can only come down a little from here in my opinion. Will take the safe money.
Additionally $DXY continues to rise wants $116 next pushing UVIX back up and SPY QQQ down some more
bet we see a green open...1:00 pumpers are already warming up
dang, bought a little SLV in AHs and now it's down 2.17% atm. Not a good decision! I'll buy more and wait, but didn't expect this rug pull.
I see appl news
but do not think its the driver of futs puking tonight, imo/ everything is about the dollar full stop, specific company bad news should already be expected, rather its priced in or not who knows until earnings season
which brings the elephant in the room, how far will Jpow and Fed go breaking the global market landscape, I don' know
total FX carnage, my dollar chart is printing an rsi over 80 tonight
Uvix should definetly fill the 15.26 gap and some more, when I look at P&F chart, Uvix target seems to be 16
Labu has been a cash cow last 2 days for me. Let my Uvix go a bit too early but I have made 2x on labu. Might see $8 in short order
Yes Large volume
AAPL warning could crash markets tomorrow. Only stock holding indices up to this point
See it and of course released the bad news yesterday $900 million settlement for bribing doctors..lol.
The news released at 817pm tonight causing LABU breakout
By Deena Beasley and Julie Steenhuysen
Sept 27 (Reuters) - An experimental Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday.
The injected drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared to a placebo, meeting the study's main goal, and offering an apparent win for the companies and potentially for patients and their families desperate for an effective treatment.
Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.
"It's not a huge effect, but it's a positive effect," said Ronald Petersen, director of the Mayo Clinic Alzheimer’s Disease Research Center in Rochester, Minnesota, adding that the results were extremely important for Alzheimer's research.
"This means that treating amyloid is a step in the right direction," he said.
Wall Street analysts, such as Salim Syed at Mizuho Securities, have said the results would be considered a "win" if lecanemab slowed the rate of decline by around 25%, and that shares of both companies could jump on the news.
Shares of Biogen and Eisai were halted, but shares of Eli Lilly & Co, which is also developing an Alzheimer's drug, were up 6.7% in after hours trade.
Lecanemab, like the companies' previous drug Aduhelm, is an antibody designed to remove those amyloid deposits. Unlike Aduhelm, lecanemab targets forms of amyloid that have not yet clumped together.
The so-called amyloid hypothesis has been challenged by some scientists, particularly after the U.S. Food and Drug Administration's controversial approval of Aduhelm in 2021 based on its plaque-clearing ability rather than proof that it helped slow cognitive decline. The decision came after the FDA's own panel of outside experts had advised against approval.
Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry.
Eisai, leader of the 50-50 partnership's lecanemab program, is seeking FDA approval under the same accelerated pathway as Aduhelm, with a decision expected in early January. But on Tuesday the Japanese drugmaker said it will use the new efficacy results to submit lecanemab for traditional FDA review.
The company said it will also seek authorization in Japan and Europe during its current fiscal year, ending March 31.
The Phase III trial evaluated the drug's ability to reduce cognitive and functional decline based on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), a numerical scale used to quantify the severity of dementia in patients in areas such as memory, orientation, judgment and problem solving and personal care.
BRAIN SWELLING
The rate of ARIA-E, a brain swelling side effect associated with anti-amyloid treatments, was 12.5% in the lecanemab group, versus 1.7% in the placebo group.
While the side effect showed up on imaging, many of these cases were not symptomatic, the companies said. Symptomatic brain swelling was seen in 2.8% of those in the lecanemab group and none of the placebo group, they said.
The trial also tracked the rate of micro hemorrhages in the brain, which occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group.
The total incidence of both conditions was 21.3% in the lecanemab group and 9.3% in the placebo group, rates that fell within an expected range, the companies said.
Petersen said the side effect was present, but much less than with Aduhelm, and "certainly tolerable."
Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.
The controversy and reluctance by some payers to cover Aduhelm led Biogen to slash the drug's price to $28,000 per year from an initial $56,000.
But Medicare, the U.S. government health plan for people 65 and older, this year said it would only pay for Aduhelm if patients were enrolled in a valid clinical trial, which sharply curtailed the medication's use. Since Alzheimer's is a disease of aging, an estimated 85% of patients eligible for the drug are covered by the government plan.
The number of Americans living with Alzheimer's is expected to rise to around 13 million by 2050 from more than 6 million currently, according to the Alzheimer's Association. Globally, that figure could rise to 139 million by 2050 without an effective treatment, according to Alzheimer's Disease International.
Other plaque-targeting antibodies in late-stage development for Alzheimer's patients include Roche Holding AG's gantenerumab and Eli Lilly's donanemab.
(Reporting by Deena Beasley in Los Angeles and Julie Steenhuysen in Chicago; Editing by Bill Berkrot and Richard Pullin)
Beautiful bullish LABU chart coming off a bottom
http://www.stockta.com/cgi-bin/analysis.pl?symb=LABU&cobrand=&mode=stock
Take that back there was massive volume last 30 minutes on LABU all the opposite something you never see in after hours trading at least in LABU. It was an endless freight train. Have you ever seen that many shares traded after hours on LABU
That was bizarre no volume after-hours and it runs like crazy for a few minutes. You say you seen it all but you never do with stock trading. At least they gave you a few minutes to cash in on those $6.95s..Happy trades
Out SPY calls, in UVXY calls and QQQ puts now. Have a nice and safe Eve.
SPY calls screaming
Fed speaker line up this week has been nothing but hawks so far
however, they were nothing but doves when inflation was building, now they're jamming up yields to break economy and keeping the narrative
can't believe anything coming out of Fed, I believe my penny stock news letters jk haha
end of day, I'll never take a short position with bear sentiment readings this extreme, all it takes is one Fed comment and algos would move so fast, would be hard to exit short position without getting killed
Stopped out for small gain. Flipped to SPY calls ODTE
strange days
seems market algos are working to fill the U gap with SPX down less than 1%, whereas, looking back 30 days or so at times when SPX was down more than 1%, 2 or 3, Vix did not catch a bid
interesting times
I’m locked and loaded again
million $ question for uvix gap
will the market fill it in this current draw down or bait & switch and fill in 2023
have no idea
Uvix Jul14 gap is 15.26 form what I see
watching everything I can
I cant go short with sentiment in extreme fear, and 3 days from Q3 start
not quick enough on the flips lol
I usually flip when I can $1 gain adds up quick looking to get back in soon
Too soon the ferry going to 330 by Friday thin air down to 330 SPY
Out UVIX again lol
SPY 330 come on let’s go go $DXY show us your cash King of flight safety
interesting too
This is all getting a bit daft isn't it?
— Sven Henrich (@NorthmanTrader) September 27, 2022
2 year yield. pic.twitter.com/3xV8A9yxnD
Followers
|
230
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
29821
|
Created
|
04/24/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |